Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Hypertension and Incident Cardiovascular Events Following Ibrutinib Initiation.

Dickerson T, Wiczer T, Waller A, Philippon J, Porter K, Haddad D, Guha A, Rogers KA, Bhatt S, Byrd JC, Woyach JA, Awan F, Addison D.

Blood. 2019 Oct 3. pii: blood.2019000840. doi: 10.1182/blood.2019000840. [Epub ahead of print]

PMID:
31582362
2.

Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib.

Kander EM, Zhao Q, Bhat SA, Hirsch J, Byrd JC, Ooka L, Wiczer T, Woyach JA, Awan FT, Rogers KA, Wang TF.

Br J Haematol. 2019 Sep 18. doi: 10.1111/bjh.16209. [Epub ahead of print] No abstract available.

PMID:
31531846
3.

Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies.

Rogers KA, Mousa L, Zhao Q, Bhat SA, Byrd JC, El Boghdadly Z, Guerrero T, Levine LB, Lucas F, Shindiapina P, Sigmund AM, Sullivan M, Wiczer TE, Woyach JA, Awan FT.

Leukemia. 2019 Oct;33(10):2527-2530. doi: 10.1038/s41375-019-0481-1. Epub 2019 May 13. No abstract available.

PMID:
31086260
4.

Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies.

Guha A, Derbala MH, Zhao Q, Wiczer TE, Woyach JA, Byrd JC, Awan FT, Addison D.

J Am Coll Cardiol. 2018 Aug 7;72(6):697-698. doi: 10.1016/j.jacc.2018.06.002. No abstract available.

5.

A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer - A real world experience.

Phelps MK, Wiczer TE, Erdeljac HP, Van Deusen KR, Porter K, Philips G, Wang TF.

J Oncol Pharm Pract. 2019 Jun;25(4):793-800. doi: 10.1177/1078155218757856. Epub 2018 Feb 20.

PMID:
29460705
6.

Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia.

DasGupta RK, Levine L, Wiczer T, Cataland S.

J Oncol Pharm Pract. 2019 Apr;25(3):567-576. doi: 10.1177/1078155217748470. Epub 2018 Jan 3.

PMID:
29298625
7.

Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib.

Wiczer TE, Levine LB, Brumbaugh J, Coggins J, Zhao Q, Ruppert AS, Rogers K, McCoy A, Mousa L, Guha A, Heerema NA, Maddocks K, Christian B, Andritsos LA, Jaglowski S, Devine S, Baiocchi R, Woyach J, Jones J, Grever M, Blum KA, Byrd JC, Awan FT.

Blood Adv. 2017 Sep 8;1(20):1739-1748. doi: 10.1182/bloodadvances.2017009720. eCollection 2017 Sep 12.

8.

Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity.

Wiczer T, Dotson E, Tuten A, Phillips G, Maddocks K.

J Oncol Pharm Pract. 2016 Jun;22(3):430-6. doi: 10.1177/1078155215594417. Epub 2015 Jul 6.

PMID:
26152702

Supplemental Content

Loading ...
Support Center